Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection

Vaccine

Volumn 16, Issue 20, 1998, Pages 2077-2084

  Sjölander, Anders ^a,b   Baldwin, Tracey M ^b   Curtis, Joan M ^b   Bengtsson, Karin Lövgren ^c   Handman, Emanuela ^b  

^a CSL LIMITED   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Iscoms; Parasite Surface Antigen 2 vaccine; Th1 responses

Indexed keywords

IMMUNOLOGICAL ADJUVANT; ISCOM; ISCOPREP 703; PARASITE ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; ESCHERICHIA COLI; FEMALE; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES; PROTEIN CONFORMATION; VACCINATION;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; ANTIGENS, SURFACE; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; INTERFERON TYPE II; ISCOMS; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED C3H; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TH1 CELLS; VACCINATION;

EID: 0032388140     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00075-9     Document Type: Article

References (41)

1. 1 Bogdan, C. and Röllinghoff, M. In: Concepts in Vaccine Development (Ed. Kaufmann, S.H.E.). Walter de Gruyter, Berlin, 1996, pp. 205-242.
2. 2 Locksley, R.M. and Louis, J.A. Immunology of leishmaniasis. Curr. Opin. Immunol. 1992, 4, 413-418.
3. 3 Wakil, A.E., Wang, Z.-E. and Locksley, R.M. Leishmania major: targeting IL-4 in successful immunomodulation of murine infection. Exp. Parasitol. 1996, 84, 214-222.
4. 4 Melby, P.C., Andrade-Narvaez, F.J., Darnell, B.J., Valencia-Pacheco, G., Tryon, V.V. and Palomo-Cetina, A. Increased expression of proinflammatory cytokines in chronic lesions of human cutaneous leishmaniasis. Infect. Immun. 1994, 62, 837-842.
5. 5 Kopf, M., Brombacher, F. and Köhler, G. et al. IL-4-deficient Balb/c mice resist infection with Leishmania major. J. Exp. Med. 1996, 184, 1127-1136.
6. 6 Ho, J.L., Badaro, R., Hatzigeorgiou, D., Reed, S.G. and Johnson, W.D. Jr.Jr. Cytokines in the treatment of leishmaniasis: from studies of immunopathology to patient therapy. Biotherapy 1994, 7, 223-235.
7. 7 Murray, P.J. and Spithill, T.W. Variants of a Leishmania surface antigen derived from a multigenic family. J. Biol. Chem. 1991, 266, 24477-24484.
8. 8 Handman, E., Osborn, A.M., Symons, F., van Driel, R. and Cappai, R. The Leishmania promastigote surface antigen 2 complex is differentially expressed during the parasite life cycle. Mol. Biochem. Parasitol. 1995, 74, 189-200.
9. 9 Symons, F.M., Murray, P.J., Osborn, A.H., Cappai, R. and Handman, E. Characterisation of a polymorphic family of integral membrane proteins in promastigotes of different Leishmania species. Mol. Biochem. Parasitol. 1994, 67, 103-113.
10. 10 Handman, E., Symons, F.M., Baldwin, T.M., Curtis, J.M. and Scheerlinck, J.-P.Y. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect. Immun. 1995, 63, 4261-4267.
11. 11 Champsi, J. and McMahon-Pratt, D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect. Immun. 1988, 56, 3272-3279.
12. 12 McMahon-Pratt, D., Rodriguez, D. and Rodriguez, J.-R. et al. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect. Immun. 1993, 61, 3351-3359.
13. 13 Steimer, K.S., Scandella, C.J., Skiles, P.V. and Haigwood, N.L. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 1991, 254, 105-108.
14. 14 Morein, B., Lövgren, K., Rönnberg, B. and Sjölander, A. Immunostimulating complexes. Clinical potential in vaccine development. Clin. Immunother. 1995, 3, 461-475.
15. 15 Villacres-Eriksson, M., Behboudi, S., Morgan, A.J., Trinchieri, G. and Morein, B. Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin-12 and its effects on the antibody response. Cytokine 1997, 9, 73-82.
16. 16 Lövgren Bengtsson, K. and Sjölander, A. Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant. Vaccine 1996, 14, 753-760.
17. 17 Nicolle, C.H. Cultures des corps de Leishman isoles de la rate dans trois cas d'anemic sptenique infantile. Bull. Soc. Pathol. Exot. 1908, 1, 121.
18. 18 Handman, E., Hocking, R.E., Mitchell, G.F. and Spithill, T.W. Isolation and characterization of infective and non-infective clones of Leishmania tropica. Mol. Biochem. Parasitol. 1983, 7, 111-126.
19. 19 Cruz, A. and Beverley, S.M. Gene replacement in parasitic protozoa. Nature 1990, 348, 171-173.
20. 20 Le Blancq, S. and Peters, W. Leishmania in the Old World: 2. Heterogeneity among L. tropica zymodemes. Trans. R. Soc. Trop. Med. Hyg. 1986, 80, 113-119.
21. 21 LeBowitz, J.H., Coburn, C.M., McMahon-Pratt, D. and Beverley, S.M. Development of a stable Leishmania expression vector and application to the study of parasite surface antigens. Proc. Natl Acad. Sci. USA 1990, 87, 9736-9740.
22. 22 Smith, D.B. and Johnson, K.S. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988, 67, 31-40.
23. 23 Morrisey, J.H. Silver stain for proteins in polyacrylamide gels: a modified procedure with enhanced uniform sensitivity. Analyt. Biochem. 1981, 117, 307-310.
24. 24 Rönnberg, B., Fekadu, M. and Morein, B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in ISCOM-matrix. Vaccine 1995, 13, 1375-1382.
25. 25 Sjölander, A., van't Land, B. and Lövgren Bengtsson, K. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell. Immunol. 1997, 177, 69-76.
26. 26 Reid, G. Soluble proteins incorporate into iscoms after covalent attachment of fatty acid. Vaccine 1992, 9, 597-602.
27. 27 Lövgren, K. and Morein, B. The requirement of lipids for the formation of immunostimulating complexes (iscoms). Biotechnol. Appl. Biochem. 1988, 10, 161-172.
28. 28 Mitchell, G.F. and Handman, E. Leishmania tropica major in mice: vaccination against cutaneous leishmaniasis in mice of high genetic susceptibility. Aust. J. Exp. Biol. Med. Sci. 1983, 61, 11-25.
29. 29 Titus, R.G., Marchand, M., Boon, T. and Louis, J.A. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 1985, 7, 545-555.
30. 30 Sjölander, A., Lövgren-Bengtsson, K., Johansson, M. and Morein, B. Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (Iscoms) containing human influenza virus envelope glycoproteins. Scand. J. Immunol. 1996, 43, 164-172.
31. + cells secreting IL-4. Int. Immunol. 1993, 5, 761-767.
32. 32 Heinzel, F.P., Sadick, M.D., Holaday, B.J., Coffman, R.L and Locksley, R.M. Reciprocal expression of interferon-γ or interleukin-4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J. Exp. Med. 1989, 169, 59-72.
33. 33 Heinzel, F.P., Sadick, M.D., Mutha, S.S. and Locksley, R.M. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis. Proc. Natl Acad. Sci. USA 1991, 88, 7011-7015.
34. 34 Maloy, K.J., Donachie, A.M. and Mowat, A.M. Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS. Eur. J. Immunol. 1995, 25, 2835-2841.
35. 35 Sjölander, A., Baldwin, T.M., Curtis, J.M. and Handman, E. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response is required for generation of immunity to leishmaniasis. J. Immunol. 1998, 160, 3949-3957.
36. 36 Murphy, N.R., Leinbach, S.S. and Hellwig, R.J. A potent, cost-effective RNase inhibitor. BioTechniques 1995, 18, 1068-1073.
37. 37 Murray, P.J., Spithill, T.W. and Handman, E. The PSA-2 glycoprotein complex of Leishmania major is a glycosylphosphatidylinositol-linked promastigote surface antigen. J. Immunol. 1989, 143, 4221-4226.
38. 38 Sjölander, S., Bolmstedt, A. and Akerblom, L. et al. N-linked glycans in the CD4-binding domain of human immunodeficiency virus type I envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity. Virology 1996, 215, 124-133.
39. 39 Drummer, H.E., Jackson, D.C. and Brown, L.E. Modulation of CD4+ T-cell recognition of influenza hemagglutinin by carbohydrate side chains located outside a T-cell determinant. Virology 1993, 192, 282-289.
40. 40 Javaherian, K., Langlois, A.J. and McDanal, C. et al. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl Acad. Sci. USA 1989, 86, 6768-6772.
41. 41 LaRosa, G.J., Davide, J.P. and Weinhold, K. et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990, 249, 932-935.